3861-99-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(AMINOSULFONYL)-5-CHLOROPHTHALIMIDE is used as an intermediate in the synthesis of Chlorexolone (C327080), a sulfonamide-based antibiotic. It plays a vital role in the production process, contributing to the development of this antibiotic, which is used to treat bacterial infections.
As an intermediate, 4-(AMINOSULFONYL)-5-CHLOROPHTHALIMIDE is essential for the creation of various other pharmaceutical compounds, potentially expanding its applications in the medical field. Its unique structure allows for further chemical reactions and modifications, making it a versatile component in the synthesis of new drugs and therapeutic agents.

InChI:InChI=1/C8H5ClN2O4S/c9-5-1-3-4(8(13)11-7(3)12)2-6(5)16(10,14)15/h1-2H,(H2,10,14,15)(H,11,12,13)

Upstream product

• 2736-23-4 2,4-dichloro-5-sulfamoylbenzoic acid 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 100448-59-7 4-chloro-2-(hydroxymethyl)benzoic acid 
• 100448-30-4 6-(phenylthio)-7-sulfamoyl-1(2H)-phthalazinone 
• 100448-27-9 2-benzyl-6-chloro-7-sulfamoyl-1(2H)-phthalazinone 
• 100448-38-2 3-Benzyl-7-chloro-4-oxo-1,2,3,4-tetrahydro-phthalazine-6-sulfonic acid amide 
• 100448-28-0 6-chloro-7-sulfamoyl-2--1-(2H)-phthalazinone 
• 100448-39-3 7-Chloro-4-oxo-3-(3-trifluoromethyl-phenyl)-1,2,3,4-tetrahydro-phthalazine-6-sulfonic acid amide 
• 100448-56-4 2-(aminocarbonyl)-5-chloro-4-sulfamoylbenzaldehyde hydrazone 

Relevant academic research and scientific papers

Synthesis, Saludiuretic, and Antihypertensive Activity of 6,7-Disubstituted 1(2H)- and 3,4-Dihydro-1(2H)-phthalazinones

The synthesis of the isomeric series 6-chloro-7-sulfamoyl-and 7-chloro-6-sulfamoyl-1(2H)-phthalazinones (1 and 2) and 6-chloro-7-sulfamoyl- and 7-chloro-6-sulfamoyl-3,4-dihydro-1(2H)-phthalazinones (3 and 4), combining structural features characteristic to furosemide and hydralazine, is described, the mechanism of the formation of 1 and 2 is discussed, and their structure-activities relationships are studied.Preliminary screening in the rat shows that series 1 and 3 exhibit diuretic and saluretic activity similar to that of chlorothiazide with, however, Na+/K+ ratios more favorable than chlorothiazide and furosemide.The compounds of series 2 and 4 are practically inactive.All four series show initial antihypertensive activity lower than that of hydralazine.However, compounds 1a, 1c, and 4a show a higher activity at 8 and/ or 24 h after administration and thus may offer a unique combination of a "loop" diuresis with direct long-acting peripheral vasodilating effects.